Published: February 13, 2012
Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
SAN DIEGO, Feb. 13, 2012 /PRNewswire/ -- Gen-Probe Incorporated (NASDAQ: GPRO) today reported financial results for the fourth quarter of 2011. Total revenues in the quarter grew 16%, to a new record of $158.2 million, while non-GAAP earnings per share (EPS) increased 18%, to a new high of $0.72.
"Gen-Probe finished 2011 strong, as blood screening sales rebounded in the fourth quarter while clinical diagnostics revenues continued their solid growth," said Carl Hull, the Company's chairman and chief executive officer. "We enter 2012 with excellent momentum based on several new product launches that are off to good starts."
Key financial results for the fourth quarter of 2011 were
($ in millions, except EPS):
Non-GAAP GAAP
-------- ----
2011 2010 Change 2011 2010 Change
---- ---- ------ ---- ---- ------
Total revenues $158.2 $136.7 +16% $158.2 $136.7 +16%
Product sales $155.2 $131.1 +18% $155.2 $131.1 +18%
Operating profit $45.8 $40.1 +14% $29.4 $36.8 -20%
Net income $33.7 $29.4 +15% $19.9 $27.2 -27%
EPS $0.72 $0.61 +18% $0.42 $0.56 -25%
Gen-Probe's GAAP results for the fourth quarter of 2011 were negatively affected by impairment charges of $12.7 million related to acquired goodwill and intangible assets.
Revenue Detail
In the fourth quarter of 2011, clinical diagnostics product sales grew by 13% compared to the prior year period. This increase was driven primarily by domestic and international growth of the APTIMA Combo 2® assay for detecting Chlamydia and gonorrhea, and by the inclusion of sales from the former GTI Diagnostics (GTI), which the Company acquired in December of 2010. Foreign currency fluctuations reduced clinical diagnostics sales by an estimated $0.1 million compared to the prior year period.
In blood screening, fourth-quarter sales increased by 30% compared to the prior year period, as expected, mainly due to greater shipments of assays and TIGRIS® instruments to Novartis, the Company's blood screening collaboration partner. Foreign currency fluctuations increased blood screening sales by an estimated $0.2 million compared to the prior year period.
Sales of research products and services in the fourth quarter of 2011 were $2.4 million, down 29% compared to the prior year period. Foreign currency fluctuations had an immaterial effect on sales of research products and services compared to the prior year period.
Fourth quarter product sales were ($ in millions):
Three Months Ended Dec. 31, Change
--------------------------- ------
2011 2010 As Constant
---- ---- Reported Currency
-------- --------
Clinical
Diagnostics $90.6 $80.1 +13% +13%
Blood Screening $62.1 $47.6 +30% +30%
Research Products $2.4 $3.4 -29% -29%
----------------- ---- ---- --- ---
and Services
------------
Total Product Sales $155.2 $131.1 +18% +18%
Collaborative research revenues in the fourth quarter of 2011 were $1.4 million, compared to $3.7 million in the prior year period, a decrease of 62% that resulted primarily from an expected decrease in funding from Novartis associated with the development of the fully automated PANTHER® instrument for the blood screening market. The PANTHER system remains on track to be launched into international blood screening markets this year.
Royalty and license revenues in the fourth quarter of 2011 were $1.6 million, compared to $1.9 million in the prior year period, a decrease of 16%.
GAAP Income Statement Details
Gross margin on product sales was 66.7% in the fourth quarter of 2011, compared to 69.4% in the prior year period. This decrease resulted mainly from higher sales of low-margin instrumentation to Novartis, which are generally a precursor to future assay sales.
Acquisition-related amortization expenses were $2.8 million in the fourth quarter of 2011, compared to $2.2 million in the prior year period, an increase of 27% that resulted mainly from the acquisition of GTI.
Research and development (R&D) expenses were $28.2 million in the fourth quarter of 2011, compared to $26.9 million in the prior year period, an increase of 5% that resulted primarily from the addition of GTI's R&D programs.
Marketing and sales expenses were $17.1 million in the fourth quarter of 2011, compared to $15.0 million in the prior year period, an increase of 14% that resulted primarily from the addition of GTI's cost structure and ongoing European commercial expansion.
General and administrative (G&A) expenses were $16.2 million in the fourth quarter of 2011, compared to $15.6 million in the prior year period, an increase of 4% that resulted mainly from the addition of GTI's cost structure.
Goodwill and asset impairment charges totaled $12.7 million in the fourth quarter of 2011. Of this charge, $8.7 million related to goodwill associated with the Company's research products and services business, which was acquired as part of the Tepnel acquisition in April of 2009, and $4.0 million related to in-process research and development intangible assets of GTI.
Total other income, net, was $0.4 million in the fourth quarter of 2011, compared to total other income, net, of $1.2 million in the prior year period, a decrease of 67%. This decrease resulted primarily from a non-cash gain in the prior year period and unfavorable exchange rate effects.
Income tax expense was $10.0 million in the fourth quarter of 2011, corresponding to an effective tax rate of 33%.
Non-GAAP Income Statement Details
In the fourth quarter of 2011, non-GAAP gross margin on product sales, R&D expenses, marketing and sales expenses, and total other income, net, were similar to the corresponding GAAP results.
Excluding transaction-related expenses and restructuring costs, non-GAAP G&A expenses were $15.6 million in the fourth quarter of 2011, compared to $14.7 million in the prior year period, an increase of 6%.
Non-GAAP income tax expense was $12.4 million in the fourth quarter of 2011, corresponding to an effective tax rate of 27%. Income tax expense was less than expected in the fourth quarter due to the utilization of foreign losses and higher ex-US sales.
Cash Flows and Balance Sheet
In the fourth quarter of 2011, Gen-Probe generated net cash of $53.4 million from operating activities, and spent $7.2 million on property, plant and equipment, leading to free cash flow of $46.2 million, a new quarterly record.
Gen-Probe continues to maintain a strong balance sheet. As of December 31, 2011, the Company had $368.0 million of cash, cash equivalents and marketable securities, and $248.0 million of short-term debt. The Company pays interest on this debt at a rate 0.6% above the one-month London Interbank Offered Rate (LIBOR), which was recently below 0.3%.
During the fourth quarter of 2011, Gen-Probe repurchased 1.7 million shares of Company stock for $100 million, corresponding to an average purchase price of $58.83 per share. This completed the $100 million repurchase plan that was announced in November of 2011.
2012 Financial Guidance
"We anticipate returning to low double-digit organic revenue growth in 2012 based on multiple new product launches that are still in their early stages," said Herm Rosenman, Gen-Probe's senior vice president, finance, and chief financial officer. "We forecast a similar rate of bottom-line growth in 2012 as we invest in these launches and in a series of R&D projects that extend our lead in assay and instrument performance. We believe that these investments position us well for solid, sustainable growth over the next several years."
Gen-Probe's 2012 financial guidance is provided below:
Non-GAAP GAAP
-------- ----
Total revenues $630 to $655 million $630 to $655 million
Product gross margins 68% to 69.5% 68% to 69.5%
Acquisition-related
amortization, N/A ~ $15 million
restructuring and other
transaction
expense
Operating margin 26.5% to 28% 24.5% to 26%
Tax rate 30.5% to 32.5% 30.5% to 32.5%
Diluted shares ~ 47 million ~ 47 million
EPS $2.50 to $2.68 $2.30 to $2.48
About Non-GAAP Financial Measures
Gen-Probe's management believes that non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance by excluding certain expenses and other items that may not be indicative of core business results. To supplement the Company's financial results for the fourth quarter of 2011 and its 2012 financial guidance, in each case presented in accordance with GAAP, Gen-Probe uses the following financial measures defined as non-GAAP by the SEC: non-GAAP net income, non-GAAP gross margin, non-GAAP R&D expenses, non-GAAP marketing and sales expenses, non-GAAP G&A expenses, non-GAAP operating profit, non-GAAP income tax rate, and non-GAAP EPS. Gen-Probe's management does not, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared and presented in accordance with GAAP. Gen-Probe believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing Gen-Probe's performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Gen-Probe's historical performance and our competitors' operating results. Gen-Probe believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Further, our reconciliations of non-GAAP to GAAP operating results, which are included on the attached tables, are presented in the format of consolidated statements of income solely to assist a reader in understanding the impact of the various adjustments to our GAAP operating results, individually and in the aggregate, and are not intended to place any undue prominence on our non-GAAP operating results.
Notes on Presentation
In this news release, all per share amounts are calculated on a diluted basis. Some totals may not foot due to rounding. Certain prior year amounts have been reclassified to conform to the current year presentation.
Webcast Conference Call
A live webcast of Gen-Probe's fourth quarter 2011 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. Call 866-501-7043 (domestic) or 203-369-1846 (international).
About Gen-Probe
Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.
Trademarks
APTIMA, APTIMA COMBO 2, PANTHER and TIGRIS are trademarks of Gen-Probe. All other trademarks are the property of their owners.
Caution Regarding Forward-Looking Statements
Any statements in this news release about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those under the heading "2012 Financial Guidance," are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning Gen-Probe's financial condition, possible or expected results of operations, the development and commercialization of new products, regulatory approvals, future milestones, growth opportunities, market trends, and management plans are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that we may not achieve our expected 2012 financial targets, (ii) the risk that we may not integrate acquisitions, such as Tepnel, Prodesse and GTI, successfully, (iii) the possibility that the market for the sale of our new products, such as our PANTHER system and PROGENSA PCA3, APTIMA HPV and APTIMA trichomonas assays, may not develop as expected, (iv) the enhancement of existing products and the development of new products may not proceed as planned, (v) the risk that investigational products, including those now in US clinical trials, may not be approved by regulatory authorities or become commercially available in the time frame we anticipate, or at all, (vi) the risk that we may not be able to compete effectively, (vii) the risk that we may not be able to maintain our current corporate collaborations or enter into new ones, (viii) our dependence on Novartis and other third parties for the distribution of some of our products, (ix) our dependence on a small number of customers, contract manufacturers and single source suppliers of raw materials, (x) changes in third-party reimbursement policies regarding our products could adversely affect sales, (xi) changes in government regulation or tax policy affecting our diagnostic products could harm our sales, increase our development costs or increase our taxes, (xii) the risk that our intellectual property may be infringed or invalidated, and (xiii) our involvement in patent and other intellectual property and commercial litigation could be expensive and could divert management's attention. This list includes some, but not all, of the factors that could affect our ability to achieve results described in forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
Contact:
Michael Watts
Vice president, investor relations and
corporate communications
858-410-8673
Gen-Probe Incorporated
Consolidated Balance Sheets - GAAP
(In thousands, except share and per share data)
December 31, December 31,
2011 2010
---- ----
Assets (Unaudited)
Current assets:
Cash and cash equivalents, including
restricted cash of $38 and $16 at
December 31, 2011 and December 31,
2010, respectively $87,021 $59,690
Marketable securities 218,789 170,648
Trade accounts receivable, net of
allowance for doubtful accounts of $320
and $355 at December 31, 2011 and
December 31, 2010, respectively 57,767 54,739
Accounts receivable - other 3,446 5,493
Inventories 77,886 66,416
Deferred income tax 8,188 13,634
Prepaid expenses 11,555 14,665
Other current assets 4,967 5,148
----- -----
Total current assets 469,619 390,433
Marketable securities, net of current
portion 62,237 259,317
Property, plant and equipment, net 176,081 160,863
Capitalized software, net 16,992 13,981
Patents, net 11,758 12,450
Goodwill 140,404 150,308
Purchased intangibles, net 106,619 120,270
License, manufacturing access fees and
other assets, net 61,738 60,175
Total assets $1,045,448 $1,167,797
========== ==========
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $12,000 $14,614
Accrued salaries and employee benefits 28,795 26,825
Other accrued expenses 12,846 13,935
Income tax payable 1,857 634
Short-term borrowings 248,000 240,000
Deferred revenue 1,238 1,166
----- -----
Total current liabilities 304,736 297,174
Non-current income tax payable 10,019 8,315
Deferred income tax 19,283 29,775
Deferred revenue, net of current portion 3,237 2,500
Other long-term liabilities 7,831 6,654
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value per
share; 20,000,000 shares authorized,
none issued and outstanding - -
Common stock, $0.0001 par value per
share; 200,000,000 shares authorized,
45,008,879 and 47,966,156 shares issued
and outstanding at December 31, 2011
and December 31, 2010, respectively 5 5
Additional paid-in capital 23,650 195,820
Accumulated other comprehensive income
(loss) (313) 678
Retained earnings 677,000 626,876
Total stockholders' equity 700,342 823,379
------- -------
Total liabilities and stockholders'
equity $1,045,448 $1,167,797
========== ==========
Gen-Probe Incorporated
Consolidated Statements of Income - GAAP
(In thousands, except per share data)
(Unaudited)
Three Months Ended Twelve Months Ended
December 31, December 31,
------------ ------------
2011 2010 2011 2010
---- ---- ---- ----
Revenues:
Product
sales $155,162 $131,093 $562,588 $522,709
Collaborative
research
revenue 1,369 3,708 7,682 14,518
Royalty
and
license
revenue 1,644 1,893 5,964 6,100
----- ----- ----- -----
Total
revenues 158,175 136,694 576,234 543,327
Operating
expenses:
Cost
of
product
sales
(excluding
acquisition-
related
intangible
amortization) 51,742 40,104 173,645 169,222
Acquisition-
related
intangible
amortization 2,760 2,231 11,061 8,847
Research
and
development 28,202 26,885 112,742 111,103
Marketing
and
sales 17,056 15,016 68,396 59,492
General
and
administrative 16,240 15,610 71,394 56,818
Goodwill
and
asset
impairment
charges 12,746 - 12,746 -
------ --- ------ ---
Total
operating
expenses 128,746 99,846 449,984 405,482
------- ------ ------- -------
Income
from
operations 29,429 36,848 126,250 137,845
Other income
(expense):
Investment
and
interest
income 1,317 1,401 8,695 11,765
Interest
expense (546) (535) (2,070) (2,216)
Gain
on
contingent
consideration - 399 - 7,994
Other-
than-
temporary
impairment
loss
on
equity
investment - - (39,482) -
Other
income
(expense),
net (364) (95) (236) (177)
---- --- ---- ----
Total
other
income
(expense),
net 407 1,170 (33,093) 17,366
--- ----- ------- ------
Income
before
income
tax 29,836 38,018 93,157 155,211
Income
tax
expense 9,977 10,780 43,033 48,274
Net
income $19,859 $27,238 $50,124 $106,937
======= ======= ======= ========
Net income per
share:
Basic $0.43 $0.57 $1.06 $2.20
===== ===== ===== =====
Diluted $0.42 $0.56 $1.04 $2.18
===== ===== ===== =====
Weighted
average
shares
outstanding:
Basic 46,117 47,827 47,254 48,560
====== ====== ====== ======
Diluted 46,944 48,455 48,387 49,033
====== ====== ====== ======
Gen-Probe Incorporated
Consolidated Statements of Income - Non-GAAP Reconciliations
(In thousands, except per share data)
(Unaudited)
Three Months Ended Three Months Ended
December 31, 2011 December 31, 2010
----------------- -----------------
Non-GAAP Adjustments GAAP Non-GAAP Adjustments GAAP
-------- ----------- ---- -------- ----------- ----
Revenues:
Product
sales $155,162 $- $155,162 $131,093 $- $131,093
Collaborative
research
revenue 1,369 - 1,369 3,708 - 3,708
Royalty
and
license
revenue 1,644 - 1,644 1,893 - 1,893
----- --- ----- ----- --- -----
Total
revenues 158,175 - 158,175 136,694 - 136,694
Operating expenses:
Cost of
product
sales
(excluding
acquisition-
related
intangible
amortization) 51,626 116 51,742 40,013 91 40,104
Acquisition-
related
intangible
amortization - 2,760 2,760 - 2,231 2,231
Research
and
development 28,160 42 28,202 26,885 - 26,885
Marketing
and
sales 17,042 14 17,056 15,016 - 15,016
General
and
administrative 15,570 670 16,240 14,670 940 15,610
Goodwill
and
asset
impairment
charges - 12,746 12,746 - - -
--- ---
Total
operating
expenses 112,398 16,348 128,746 96,584 3,262 99,846
------- ------ ------- ------ ----- ------
Income
from
operations 45,777 (16,348) 29,429 40,110 (3,262) 36,848
Other income
(expense):
Investment
and
interest
income 1,317 - 1,317 1,401 - 1,401
Interest
expense (546) - (546) (535) - (535)
Gain on
contingent
consideration - - - - 399 399
Other
income
(expense),
net (364) - (364) (95) - (95)
---- --- ---- --- --- ---
Total
other
income,
net 407 - 407 771 399 1,170
--- --- --- --- --- -----
46,184 (16,348) 29,836 40,881 (2,863) 38,018
Income before
income tax
Income
tax
expense 12,441 (2,464) 9,977 11,437 (657) 10,780
Net
income $33,743 $(13,884) $19,859 $29,444 $(2,206) $27,238
======= ======== ======= ======= ======= =======
Net income per
share:
Basic $0.73 $(0.30) $0.43 $0.61 $(0.04) $0.57
===== ====== ===== ===== ====== =====
Diluted $0.72 $(0.30) $0.42 $0.61 $(0.05) $0.56
===== ====== ===== ===== ====== =====
Weighted average
shares
outstanding:
Basic 46,117 46,117 47,827 47,827
====== ====== ====== ======
Diluted 46,944 46,944 48,455 48,455
====== ====== ====== ======
Gen-Probe Incorporated
Consolidated Statements of Income - Non-GAAP Reconciliations
(In thousands, except per share data)
(Unaudited)
Twelve Months Ended Twelve Months Ended
December 31, 2011 December 31, 2010
----------------- -----------------
Non-GAAP Adjustments GAAP Non-GAAP Adjustments GAAP
-------- ----------- ---- -------- ----------- ----
Revenues:
Product
sales $562,588 $- $562,588 $522,709 $- $522,709
Collaborative
research
revenue 7,682 - 7,682 14,518 - 14,518
Royalty
and
license
revenue 5,964 - 5,964 6,100 - 6,100
----- --- ----- ----- --- -----
Total
revenues 576,234 - 576,234 543,327 - 543,327
Operating expenses:
Cost of
product
sales
(excluding
acquisition-
related
intangible
amortization) 173,216 429 173,645 168,860 362 169,222
Acquisition-
related
intangible
amortization - 11,061 11,061 - 8,847 8,847
Research
and
development 112,633 109 112,742 111,103 - 111,103
Marketing
and
sales 68,359 37 68,396 59,492 - 59,492
General
and
administrative 66,170 5,224 71,394 54,491 2,327 56,818
Goodwill
and
asset
impairment
charges - 12,746 12,746 - - -
--- ---
Total
operating
expenses 420,378 29,606 449,984 393,946 11,536 405,482
------- ------ ------- ------- ------ -------
Income
from
operations 155,856 (29,606) 126,250 149,381 (11,536) 137,845
Other income
(expense):
Investment
and
interest
income 8,695 - 8,695 11,765 - 11,765
Interest
expense (2,070) - (2,070) (2,216) - (2,216)
Gain on
contingent
consideration - - - - 7,994 7,994
Other-
than-
temporary
impairment
loss on
equity
investment - (39,482) (39,482) - - -
Other
income
(expense),
net (236) - (236) (177) - (177)
Total
other
income
(expense),
net 6,389 (39,482) (33,093) 9,372 7,994 17,366
----- ------- ------- ----- ----- ------
Income
before
income
tax 162,245 (69,088) 93,157 158,753 (3,542) 155,211
Income
tax
expense 49,226 (6,193) 43,033 51,303 (3,029) 48,274
Net
income $113,019 $(62,895) $50,124 $107,450 $(513) $106,937
======== ======== ======= ======== ===== ========
Net income per
share:
Basic $2.39 $(1.33) $1.06 $2.21 $(0.01) $2.20
===== ====== ===== ===== ====== =====
Diluted $2.34 $(1.30) $1.04 $2.19 $(0.01) $2.18
===== ====== ===== ===== ====== =====
Weighted average
shares
outstanding:
Basic 47,254 47,254 48,560 48,560
====== ====== ====== ======
Diluted 48,387 48,387 49,033 49,033
====== ====== ====== ======
Gen-Probe Incorporated
Consolidated Statements of Cash Flows - GAAP
(In thousands)
(Unaudited)
Twelve Months Ended
December 31,
------------
2011 2010
---- ----
Operating activities:
Net income $50,124 $106,937
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 46,569 44,529
Amortization of premiums on
investments, net of accretion of
discounts 9,592 9,573
Stock-based compensation 24,741 24,075
Excess tax benefit from employee
stock-based compensation (5,080) (3,692)
Deferred revenue 850 (1,808)
Deferred income tax (4,220) (3,745)
Other-than-temporary impairment
loss on equity investment 39,482 -
Goodwill and asset impairment charges 12,746 -
Gain on contingent consideration - (7,994)
Loss on disposal of property and
equipment 364 1,065
Changes in assets and liabilities:
Trade and other accounts receivable (1,112) 2,649
Inventories (11,168) (1,154)
Prepaid expenses 408 3,055
Other current assets 384 (360)
Other long-term assets 7,164 (559)
Accounts payable (2,698) (6,265)
Accrued salaries and employee
benefits 2,981 (133)
Other accrued expenses (1,398) (4,417)
Income tax payable 10,313 7,688
Other long-term liabilities 1,211 122
Net cash provided by operating
activities 181,253 169,566
------- -------
Investing activities:
Proceeds from sales and maturities of
marketable securities 489,241 427,821
Purchases of marketable securities (395,190) (401,434)
Purchases of property, plant and
equipment (41,664) (30,716)
Purchase of capitalized software (6,053) (3,891)
Purchases of intangible assets,
including licenses and manufacturing
access fees (5,259) (2,513)
Net cash paid for business
combinations - (53,000)
Cash paid for investment in Roka
Bioscience (3,980) -
Cash paid for investment in Pacific
Biosciences - (50,000)
Other (209) (738)
Net cash provided by (used in)
investing activities 36,886 (114,471)
------ --------
Financing activities:
Repurchase and retirement of common
stock (250,000) (99,935)
Proceeds from issuance of common
stock and employee stock purchase
plan 49,932 31,830
Payment of contingent consideration - (10,000)
Repurchase and retirement of
restricted stock for payment of
taxes (1,615) (1,257)
Excess tax benefit from employee
stock-based compensation 5,080 3,692
Borrowings, net 8,000 (228)
Net cash used in financing activities (188,603) (75,898)
-------- -------
Effect of exchange rate changes on
cash and cash equivalents (2,205) (2,123)
------ ------
Net increase (decrease) in cash and
cash equivalents 27,331 (22,926)
Cash and cash equivalents at the
beginning of period 59,690 82,616
Cash and cash equivalents at the end
of period $87,021 $59,690
======= =======
SOURCE Gen-Probe Incorporated
Copyright © 2012, PRNewswire
Copyright © 2012, NewsBlaze,
Daily News
Search News
